Journal
LUPUS
Volume 23, Issue 12, Pages 1320-1323Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/0961203314540354
Keywords
Anti-domain I antibodies; thrombosis; pregnancy morbidity
Categories
Funding
- Arthritis Research UK Programme Grant [19423]
- Versus Arthritis [19423] Funding Source: researchfish
Ask authors/readers for more resources
IgG antiphospholipid antibodies (aPL) against (2)-glycoprotein I ((2)GPI) can target any of its five domains; however, aPL against the N-terminal domain (anti-DI, aDI) are considered the most clinically relevant in the antiphospholipid syndrome (APS). Circulating levels of aDI are elevated in patients with APS compared with disease and healthy controls, and crucially aDI are prothrombotic in invivo and invitro models. In addition, human recombinant DI has been shown to abrogate aPL-induced thrombosis invivo. Therefore, although the potential of utilizing DI for management of APS is not yet fully defined, there is promise that DI could prove valuable both as a diagnostic and therapeutic tool.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available